Neil Stahl Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Neil Stahl is EVP Research and Development of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 48,829 shares of REGN, which is worth approximately $27.9 Million. The most recent transaction as insider was on Dec 11, 2021, when has been sold 753 shares (Common Stock) at a price of $664.34 per share, resulting in proceeds of $500,248. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48.8K

0% 3M change

4.25% 12M change

Total Value Held $27.9 Million

NEIL STAHL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 11 2021	SELL Payment of exercise price or tax liability	$500,248 $664.34 p/Share	753 Reduced 1.4%	53,130 Common Stock
Dec 08 2021	BUY Grant, award, or other acquisition	-	2,926 Added 5.15%	53,883 Common Stock
Dec 03 2021	SELL Payment of exercise price or tax liability	$31,845,123 $632.45 p/Share	50,352 Reduced 49.7%	50,957 Common Stock
Dec 03 2021	BUY Exercise of conversion of derivative security	$12,986,925 $179.13 p/Share	72,500 Added 41.71%	101,309 Common Stock
Nov 29 2021	SELL Bona fide gift	-	4,605 Reduced 13.78%	28,809 Common Stock
May 17 2021	SELL Open market or private sale	$9,100,758 $519.42 p/Share	17,521 Reduced 41.92%	24,280 Common Stock
May 14 2021	SELL Payment of exercise price or tax liability	$18,073,300 $516.69 p/Share	34,979 Reduced 45.56%	41,801 Common Stock
May 14 2021	BUY Exercise of conversion of derivative security	$6,067,950 $115.58 p/Share	52,500 Added 51.72%	49,005 Common Stock
Feb 25 2021	SELL Bona fide gift	-	435 Reduced 1.76%	24,280 Common Stock
Dec 09 2020	BUY Grant, award, or other acquisition	-	1,688 Added 6.39%	24,715 Common Stock
May 11 2020	SELL Open market or private sale	$3,018,385 $568.97 p/Share	5,305 Reduced 31.8%	11,380 Common Stock
May 08 2020	SELL Payment of exercise price or tax liability	$4,034,020 $560.67 p/Share	7,195 Reduced 30.13%	16,685 Common Stock
May 08 2020	BUY Exercise of conversion of derivative security	$650,375 $52.03 p/Share	12,500 Added 34.36%	23,880 Common Stock
Apr 14 2020	SELL Open market or private sale	$2,862,177 $520.68 p/Share	5,497 Reduced 32.57%	11,380 Common Stock
Apr 13 2020	SELL Payment of exercise price or tax liability	$3,878,647 $511.56 p/Share	7,582 Reduced 31.0%	16,877 Common Stock
Apr 13 2020	BUY Exercise of conversion of derivative security	$680,500 $52.03 p/Share	13,079 Added 34.84%	24,459 Common Stock
Feb 27 2020	SELL Open market or private sale	$4,677,437 $451.97 p/Share	10,349 Reduced 47.63%	11,380 Common Stock
Feb 26 2020	SELL Payment of exercise price or tax liability	$6,620,640 $451.89 p/Share	14,651 Reduced 40.27%	21,729 Common Stock
Feb 26 2020	SELL Bona fide gift	-	750 Reduced 3.45%	20,979 Common Stock
Feb 26 2020	BUY Exercise of conversion of derivative security	$1,300,750 $52.03 p/Share	25,000 Added 40.73%	36,380 Common Stock
Feb 13 2020	SELL Open market or private sale	$4,132,989 $402.12 p/Share	10,278 Reduced 47.46%	11,380 Common Stock
Feb 12 2020	SELL Payment of exercise price or tax liability	$5,923,249 $402.34 p/Share	14,722 Reduced 40.47%	21,658 Common Stock
Feb 12 2020	BUY Exercise of conversion of derivative security	$1,300,750 $52.03 p/Share	25,000 Added 40.73%	36,380 Common Stock

Neil Stahl

EVP Research and Development

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account